News from kahr medical A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Apr 01, 2021, 07:35 ET KAHR Announces Exclusive Licensing Agreement with Thomas Jefferson University for Novel Platform of Bi- and Tri-Specific Fusion Proteins for Cancer Immunotherapy

KAHR, a cancer immunotherapy company developing novel multifunctional immuno-recruitment proteins, announced today that it has entered into a...

Nov 12, 2020, 06:45 ET KAHR Announces First Patient Dosed in Phase 1/2 Clinical Trial of DSP107, Bi-Functional CD47x41BB Candidate for the Treatment of Solid Tumors

KAHR, a cancer immunotherapy company developing novel multifunctional immuno-recruitment proteins, today announced dosing of the first patient in its ...

Oct 15, 2020, 08:36 ET KAHR Announces Addition of Prof. Hagop M. Kantarjian to Its Clinical Advisory Board

KAHR, a cancer immunotherapy company developing novel multifunctional immuno-recruitment proteins, today announced that Prof. Hagop M. Kantarjian,...

Oct 12, 2020, 06:30 ET KAHR Announces Oral Presentation at the 62nd American Society of Hematology (ASH) Annual Meeting

KAHR, a cancer immunotherapy company developing novel multifunctional immuno-recruitment proteins, today announced that an abstract reporting...

Oct 05, 2020, 03:00 ET KAHR Announces Two Key Appointments to Strengthen Leadership Team

KAHR, a cancer immunotherapy company developing novel multifunctional immuno-recruitment proteins, today announced that Aron Knickerbocker has been...

Aug 13, 2020, 07:30 ET KAHR Medical to Present at Oppenheimer's Private Life Sciences Company Call Series

KAHR Medical today announced the company's participation in Oppenheimer's Private Life Sciences Company Call Series taking place virtually August...

Aug 12, 2020, 03:00 ET KAHR Medical Announces FDA Clearance of IND Application for DSP107, anti-CD47 Candidate for the Treatment of Solid Tumors

KAHR Medical, a cancer immunotherapy company developing novel bi-functional fusion proteins, announced today that the U.S. Food and Drug...

Feb 25, 2020, 04:31 ET KAHR Medical Raises $18 Million in Private Funding Round

KAHR Medical Ltd., a biopharmaceutical company developing a novel drug platform based on bi-functional, immunotherapeutic fusion proteins known as...

Sep 09, 2019, 07:10 ET KAHR Medical Announces Clinical Trial Collaboration to Evaluate DSP107 in Combination With a PD-L1 Checkpoint Inhibitor in Advanced Lung Cancer Patients

KAHR Medical, a biopharmaceutical company developing a novel drug platform based on bi-functional, immunotherapeutic fusion proteins known as DSP...